I'm guessing the market was previously using Europe sales as a forward indicator for US sales growth, given iTrack Advance was approved there first. It saw the immediate growth in Europe post approval quickly flatten, so it must have assumed the same would happen in the US (forgetting the fact that they weren't investing any resources in growth outside the USA). I'd say this announcement has definitely confirmed the sales growth we have seen isn't one off, and will be sustained for many years to come. Now that they are doubling their sales force I'm sure Sight Sciences are becoming quite concerned, and I'm sure other larger companies may be considering M&A options involving iTrack Advance, given its market leading status.
- Forums
- ASX - By Stock
- EYE
- Ann: EYE February sales update
Ann: EYE February sales update, page-10
Featured News
Add EYE (ASX) to my watchlist
(20min delay)
|
|||||
Last
16.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $36.64M |
Open | High | Low | Value | Volume |
16.0¢ | 16.0¢ | 15.5¢ | $65.26K | 412.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 76733 | 15.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
16.0¢ | 239407 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 76733 | 0.155 |
5 | 139500 | 0.150 |
9 | 619724 | 0.145 |
11 | 450030 | 0.140 |
2 | 14500 | 0.135 |
Price($) | Vol. | No. |
---|---|---|
0.160 | 239407 | 5 |
0.165 | 100000 | 1 |
0.170 | 200000 | 3 |
0.175 | 100000 | 1 |
0.180 | 100000 | 1 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
EYE (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online